Second Covid-19 vaccine trial commences in Russia

29th July 2020 (Last Updated July 29th, 2020 07:13)

Clinical trials of second Covid-19 vaccine candidate in Russia have commenced at the Vector virology institute in Siberia, according to RIA news agency.

Second Covid-19 vaccine trial commences in Russia
The trials aim to assess the safety and tolerability of the vaccine components. Credit: Jernej Furman.

Clinical trials of second Covid-19 vaccine candidate in Russia have commenced at the Vector virology institute in Siberia, according to RIA news agency.

The first five participants were dosed on 27 July. Citing consumer safety watchdog Rospotrebnadzor, RIA said that the next volunteer would be vaccinated on 30 July.

Reuters added that a government clinical trials register shows that the institute is assessing a peptide vaccine based on a platform initially developed for Ebola.

The trial of the Covid-19 vaccine candidate is expected to scale up to 100 participants aged 18 and 60 years.

Based on the World Health Organization (WHO) records, the Vector virology institute is working on six different potential Covid-19 vaccines.

The country’s first Covid-19 vaccine candidate had already entered initial trials. The candidate is an adenovirus-based vaccine developed by the Gamaleya National Research Center for Epidemiology and Microbiology.

An early stage trial was completed this month and the vaccine is expected to advance into large-scale trials next month.

Russia granted authorisation for clinical trials of two formulations of Gamaleya’s  Covid-19 vaccine candidate.

An intramuscular solution of the vaccine was tested at the Burdenko Military Hospital while Sechenov University assessed the vaccine in the form a powder for the preparation of an intramuscular solution.

Data found that the candidate was safe and induced an immune response in participants.

The primary objective of the trial was to assess the safety and tolerability of the Covid-19 vaccine components in the first group of 18 subjects.

For 28 days following vaccination, the vital signs of the participants were within normal limits, without any report of serious adverse events, health complaints, complications, or adverse reactions.